Clinical usefulness of measurements of urinary deoxypyridinoline (DPD) in patients with postmenopausal osteoporosis receiving intermittent cyclical etidronate: Advantage of free form of DPD over total DPD in predicting treatment efficacy

Journal of Bone and Mineral Metabolism

Volumn 21, Issue 4, 2003, Pages 217-224

  Kitatani, Kayoko ^a   Nakatsuka, Kiyoshi ^a   Naka, Hiroshi ^a   Miki, Takami ^a   Morii, Hirotoshi ^b   Nishizawa, Yoshiki ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b AINO UNIVERSITY   (Japan)

Author keywords

Cyclical etidronate; Deoxypyridinoline; Intermittent; Minimum significant change; Osteoporosis; Receiver operating characteristic analysis

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALKALINE PHOSPHATASE BONE ISOENZYME; BIOLOGICAL MARKER; CALCIUM; DEOXYPYRIDINOLINE; ETIDRONIC ACID; OSTEOCALCIN; ALKALINE PHOSPHATASE; AMINO ACID;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE METABOLISM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DISEASE MARKER; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; POSTMENOPAUSE OSTEOPOROSIS; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEIVER OPERATING CHARACTERISTIC; SIGNAL NOISE RATIO; TREATMENT OUTCOME; URINALYSIS; DRUG EFFECT; METABOLISM; MIDDLE AGED; PREDICTION AND FORECASTING; ROC CURVE; SENSITIVITY AND SPECIFICITY; URINE;

AGED; ALKALINE PHOSPHATASE; AMINO ACIDS; BIOLOGICAL MARKERS; BONE DENSITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ENZYME-LINKED IMMUNOSORBENT ASSAY; ETIDRONIC ACID; FEMALE; HUMANS; MIDDLE AGED; OSTEOCALCIN; OSTEOPOROSIS, POSTMENOPAUSAL; PREDICTIVE VALUE OF TESTS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 2142824139     PISSN: 09148779     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Consensus Development Conference (1993) Diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 94:646-650
2. WHO Study Group (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. World Health Organization, Geneva
3. Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara S, Shiraki M, Kushida K, Miyamoto S, Sone S, Nishimura J, Oh-Hashi Y, Hosoi T, Gorai I, Tanaka H, Igai T, Kishimoto H (2001) Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 19:331-337
4. Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J (2000) Committee of Scientific Advisers of the International Osteoporosis Foundation. The use of biochemical markers of bone turnover in osteoporosis. Osteoporosis Int 11 (Suppl 6):S2-S17
5. Nishizawa Y, Nakamura T, Ohata H, Kusida K, Gorai I, Shiraki M, Fukunaga M, Hosoi T, Miki T, Nakatsuka K, Miura M (2001) Guideline on the use of biochemical markers of bone turnover in osteoporosis (2002) J Bone Miner Metab 19:338-344
6. Iki M, Kajita E, Dohi Y, Nishino H, Kusaka Y, Tsuchida C, Yamamoto K, Ishii Y (1996) Age, menopause, bone turnover markers and lumbar bone loss in healthy Japanese women. Maturitas 25:59-67
7. Nakatsuka K, Miki T, Sekiya K, Kawakami H, Hirota Y, Miura M, Obi Y, Nishizawa Y, Morii H (1997) Clinical application of immunoassay for urinary total excretion of deoxypyridinoline in patients with osteoporosis. J Bone Miner Metab 15:153-159
8. Logue FC, Beastall GH, Fraser WD, O'Reilly DS (1990) Intact parathyroid hormone assay. BMJ 300:210-211
9. Hata K, Tokuhiro H, Nakatsuka K, Miki T, Nishizawa Y, Morii H, Miura M (1996) Measurement of bone-specific alkaline phosphatase by an immunoselective enzyme assay method. Ann Clin Biochem 33:127-131
10. Nakatsuka K, Miki T, Nishizawa Y, Tabata T, Tnoue T, Morii H, Ogata E (1991) Circulating bone Gla protein in end-stage renal disease determined by newly developed two-site immunoradiometric assay. Contrib Nephrol 90:147-154
11. Lau KH, Onishi T, Wergedal JE, Singer FR, Baylink DJ (1987) Characterization and assay of tartrate-resistant acid phosphatase activity in serum: potential use to assess bone resorption. Clin Chem 33:458-462
12. Black D, Duncan A, Robins SP (1988) Quantitative analysis of the pyridinium crosslinks of collagen in urine using ion-paired reverse-phase high-performance liquid chromatagraphy. Anal Biochem 169:197-203
13. Robins SP, Woitge H, Hesley R, Ju J, Seyedin S, Seibel MJ (1994) Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. J Bone Miner Res 9:1643-1649
14. Fleisch H, Russell RG, Francis MD (1969) Diphosphonates inhibit hydroxy apatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 165:1262-1264
15. Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, Licata AA, Ross P, Woodson GC III, Yanover MJ (1990) Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 323:73-79
16. Storm T, Kollerup G, Thamsborg G, Genant HK, Sorensen OH (1996) Five years of clinical experience with intermittent cyclical etidronate for postmenopausal osteoporosis. J Rheumatol 23:1560-1564
17. Miller PD, Watts NB, Licata AA, Harris ST, Genant HK, Wasnich RD, Ross PD, Jackson RD, Hoseyni MS, Schoenfeld SL, Valent DJ (1997) Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment. Am J Med 103:468-476
18. Robins SP, Duncan A (1987) Pyridinium crosslinks of bone collagen and their location in peptides isolated from rat femur. Biochim Biophys Acta 914:233-239
19. Seyedin SM, Kung VT, Daniloff YN, Hesley RP, Gomez B, Nielsen LA, Rosen HN, Znk RF (1993) Immunoassay for urinary pyridinoline: the new marker of bone resorption. J Bone Miner Res 8:635-641
20. Hannon R, Blumsohn A, Naylor K, Eastell R (1998) Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biochemical variability. J Bone Miner Res 13:1124-1133